Search research articles

Search research articles

Related Experiment Videos

Extrapulmonary tuberculosis in immunocompetent adults.

Arif Atahan Cagatay¹, Yasar Caliskan, Selcuk Aksoz

¹Departments of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Istanbul University, Turkey. atayon@yahoo.com

Scandinavian Journal of Infectious Diseases

|March 15, 2005

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Apolipoprotein L1 genetic testing, family history of hypertension, and kidney disease in a Midwestern U.S. cohort.

Frontiers in nephrology·2026

Same author

Dynamic hyperinflammatory response assessment using HIC scores in COVID-19: application to a large series of patients receiving anakinra.

Frontiers in immunology·2026

Same author

Gene-disease relationships for glomerular phenotypes: expert recommendations from ClinGen.

Nature reviews. Nephrology·2026

Same author

The impact of previous brucellosis treatment on the clinical course of neurobrucellosis: a multicentre retrospective study.

BMC infectious diseases·2026

Same author

Clinical Utility of Standardized Genetic Testing in Kidney Transplant Candidate Evaluation.

Transplantation direct·2026

Same author

Ocular Syphilis in Individuals with and Without HIV: A Single-Center University Hospital Experience.

Pathogens (Basel, Switzerland)·2026

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Extrapulmonary tuberculosis (EPT) remains a significant public health concern. A history of pulmonary tuberculosis is a key risk factor for developing EPT, highlighting the need for continued vigilance and effective treatment strategies.

Area of Science:

Infectious Diseases
Public Health
Clinical Medicine

Background:

Tuberculosis (TB) is a major global health challenge, causing significant morbidity and mortality.
While typically affecting the lungs, TB can manifest in other organs as extrapulmonary tuberculosis (EPT) or disseminated TB.
EPT poses a substantial public health burden, necessitating a deeper understanding of its epidemiology and risk factors.

Purpose of the Study:

To retrospectively analyze the incidence, clinical presentations, and risk factors associated with extrapulmonary tuberculosis (EPT).
To identify specific patient groups and clinical histories that predispose individuals to developing EPT.
To evaluate the severity and common sites of EPT to inform public health strategies and treatment approaches.

Main Methods:

Related Experiment Videos

Retrospective analysis of 252 patients diagnosed with EPT between January 1, 1991, and June 30, 2003.
Definition of EPT included clinical, laboratory, imaging, and/or histopathological evidence of mycobacterial infection outside the lungs or hilar lymph nodes.
Statistical analysis to determine the incidence, common clinical sites, and significant risk factors for EPT, with a focus on prior pulmonary TB.

Main Results:

Tuberculous lymphadenitis was the most frequent clinical presentation of EPT, accounting for 36.5% of cases.
Nearly half (47.2%) of the patients presented with severe EPT, while 52.8% had less severe forms.
A history of pulmonary tuberculosis was identified as a significant risk factor for the development of EPT (p <0.05).

Conclusions:

Extrapulmonary tuberculosis continues to be a critical public health issue requiring ongoing attention and resource allocation.
Pulmonary tuberculosis plays a pivotal role in the pathogenesis of EPT, underscoring the importance of early detection and management of primary lung infections.
A 12-month therapeutic regimen for EPT may be a viable option, offering acceptable adverse effects and low relapse rates, warranting further clinical consideration.